I am absolutely sure!
The 29% reduction across the whole patient sample was dropped sometime before 27 October 2020, as the data analysis received further refinement. Check all the announcements prior to 27 Oct 20 and all those after.
Since the 27 October 2020 announcement the proteinuria reduction has consistently been 35%, comprising 18% contribution from the Irbesartin standard of care and 17% from the DXB-200 (and nil% placebo).
There is no inconsistency, based on the correction presented 27 Oct 20.
PS - 'mean' = 'average'. They are exactly the same thing!
Ann: AGM Presentation, page-20
-
- There are more pages in this discussion • 58 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
45.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $250.5M | |||
| Open | High | Low | Value | Volume |
| 46.5¢ | 47.5¢ | 45.5¢ | $934.4K | 2.015M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 548864 | 45.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 46.0¢ | 35747 | 5 |
View Market Depth
| Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
| DXB (ASX) Chart |